Biomarkers in Monitoring Medication Treatment in Relapsing-Remitting Multiple Sclerosis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Multiple Sclerosis
- Relapsing Remitting Multiple Sclerosis
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
The following techniques will be applied: Neurophysiological testing will be performed with navigated transcranial magnetic stimulation (nTMS) incorporating an individual MRI of each subject's brain performed on 1,5 MRI scanner using a series of neuropsychological protocols; Electromyoneurography (E...
The following techniques will be applied: Neurophysiological testing will be performed with navigated transcranial magnetic stimulation (nTMS) incorporating an individual MRI of each subject's brain performed on 1,5 MRI scanner using a series of neuropsychological protocols; Electromyoneurography (EMNG) assessment of lower and upper extremities for motor and sensory nerves; Neuropsychological assessment will include the general questionnaire and battery of cognitive and psychological tests; Immunoassays on blood samples include testing with four antibodies to monocyte markers; Clinical examinations include neurological, biochemical, neuroradiological and neuropsychological testing. The participants with relapsing-remitting MS will be tested in 3 phases: before the intake of steroids, 5 weeks after taking the steroids and 6 months after taking the steroids. In each phase, the overall testings will be accomplished in three days.
Tracking Information
- NCT #
- NCT04604041
- Collaborators
- University Hospital of Split
- Investigators
- Principal Investigator: Maja Rogi? Vidakovi?, MSc, PhD University of Split, School of Medicine
Get Well Soon